Stockscreener 앱 받기
0.4942
13.06%
0.0622
전일 마감가:
$0.432
열려 있는:
$0.49
하루 거래량:
252.81K
Relative Volume:
2.05
시가총액:
$31.39M
수익:
$37.20M
순이익/손실:
$-11.85M
주가수익비율:
-2.5901
EPS:
-0.1908
순현금흐름:
$-10.59M
1주 성능:
+15.60%
1개월 성능:
-1.85%
6개월 성능:
-23.69%
1년 성능:
-59.97%
1일 변동 폭
$0.4805
$0.50
1주일 범위
$0.3695
$0.50
52주 변동 폭
$0.3695
$1.39
Cytosorbents Corp Stock (CTSO) Company Profile
명칭
Cytosorbents Corp
전화
973-329-8885
주소
305 COLLEGE ROAD EAST, PRINCETON, NJ
Compare CTSO vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTSO
Cytosorbents Corp
|
0.4999 | 27.13M | 37.20M | -11.85M | -10.59M | -0.1908 |
ABT
Abbott Laboratories
|
89.61 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.26 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
81.22 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
46.51 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.19 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-09-07 | 개시 | B. Riley Securities | Buy |
| 2021-10-14 | 재개 | B. Riley Securities | Buy |
| 2020-09-17 | 개시 | Jefferies | Buy |
| 2020-09-01 | 개시 | SVB Leerink | Outperform |
| 2017-08-08 | 재확인 | Maxim Group | Buy |
| 2016-10-26 | 개시 | Aegis Capital | Buy |
| 2016-05-24 | 개시 | Maxim Group | Buy |
| 2015-10-29 | 업그레이드 | WBB Securities | Speculative Buy → Buy |
| 2015-05-12 | 재확인 | MLV & Co | Buy |
| 2015-04-01 | 재확인 | MLV & Co | Buy |
| 2015-03-05 | 개시 | MLV & Co | Buy |
| 2015-02-25 | 개시 | WBB Securities | Speculative Buy |
| 2015-01-27 | 재확인 | H.C. Wainwright | Buy |
모두보기
Cytosorbents Corp 주식(CTSO)의 최신 뉴스
Cytosorbents CEO Phillip Chan buys $104,897 in company stock - Investing.com
CTSO | Cytosorbents Corp. FinancialsIncome Statement - Quiver Quantitative
Cytosorbents (CTSO) CEO boosts stake with 261,469-share open-market buy - Stock Titan
Cytosorbents Corporation (NASDAQ:CTSO): Is Breakeven Near? - simplywall.st
CytoSorbents (NASDAQ: CTSO) asks shareholders to OK 1-for-5–1-for-20 reverse split - Stock Titan
CytoSorbents Corp stock (US23283M1018): Q1 miss keeps focus on growth and cash runway - AD HOC NEWS
CTSO Technical Analysis & Stock Price Forecast - Intellectia AI
CytoSorbents Corp stock (US23283M1018): analyst sentiment and low share price keep focus on Nasdaq-l - AD HOC NEWS
CytoSorbents Corp stock (US23283M1018): Nasdaq price action and valuation metrics in focus - AD HOC NEWS
Cytosorbents Earnings Call Balances Progress and Pressure - The Globe and Mail
Why Cytosorbents (CTSO) Just Dropped -1.78% — What to Watch 2026-05-20Expert Momentum Signals - Newser
Earnings call transcript: CytoSorbents Q1 2026 misses forecasts, stock falls - Investing.com
Cytosorbents (CTSO) Q1 2026 Disappoints — EPS $-0.08 Below $-0.06 ViewsDividend Growth Analysis - Newser
Cytosorbents Corporation (NASDAQ:CTSO) Q1 2026 Earnings Call Transcript - Insider Monkey
Cytosorbents Earnings Call Balances Progress And Pressure - The Globe and Mail
CytoSorbents Corp (CTSO) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic Growth - GuruFocus
Is CytoSorbents (CTSO) a Value Trap Despite 39.9% Undervaluation - GuruFocus
CytoSorbents (CTSO) Reports Q1 Revenue Growth - GuruFocus
Transcript: CytoSorbents Q1 2026 Earnings Conference Call - Yahoo Finance
Cytosorbents Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Cytosorbents Corp 1Q 2026: Revenue $8.86M, EPS ($0.08) — 10-Q Summary - TradingView
CYTOSORBENTS ($CTSO) Releases Q1 2026 Earnings - Quiver Quantitative
CytoSorbents (CTSO) posts wider Q1 2026 loss and flags going-concern risk - Stock Titan
CytoSorbents (NASDAQ: CTSO) details DrugSorb-ATR FDA path and Q1 2026 results - Stock Titan
CytoSorbents: Q1 Earnings Snapshot - marketscreener.com
CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update - Fidelity
CytoSorbents Q1 earnings preview - MSN
Cytosorbents Corp expected to post a loss of 5 cents a shareEarnings Preview - TradingView
CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026 - Quantisnow
CTSO (Cytosorbents) revenue climbs 4.1% to $37.1M in Q1 but loss widens, shares flat.Earnings Yield Analysis - Newser
CytoSorbents to Report First Quarter 2026 Financial Results and Recent Business Highlights - BioSpace
CTSO Cytosorbents shares climb 6 percent today despite reporting a wider than expected Q4 2025 per share loss.Mid-Term Outlook - thelegaladvocate.com
CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - Aktiellt
CTSO Analyst Rating Update: HC Wainwright Lowers Price Target | - GuruFocus
Executive Compensation, Stock Options, and Corporate Governance Disclosure - Minichart
Governance, pay and ownership detailed in CytoSorbents (NASDAQ: CTSO) 10-K/A - Stock Titan
CytoSorbents implemented workforce and cost reduction program - TipRanks
Cytosorbents granted 180-day extension by Nasdaq to meet minimum bid price - Investing.com South Africa
CytoSorbents Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView — Track All Markets
Nasdaq gives CytoSorbents (NASDAQ: CTSO) more time on $1 bid rule - Stock Titan
Cytosorbents (CTSO) Takes Regulatory Gamble While Insiders Remain on the Sidelines and Institutions Are Divided - Bitget
CytoSorbents Corp (HQE1.MU) Stock Price, News, Quote & History - Yahoo! Finance Canada
CytoSorbents Corp (HQE1.MU) stock price, news, quote and history - Yahoo Finance UK
CytoSorbents Corporation 2025 Annual Report: Blood Purification Technologies, Clinical Trials, and Regulatory Insights - Minichart
Cytosorbents 10-K: Revenue $37.1M, EPS not disclosed - TradingView
CytoSorbents (NASDAQ: CTSO) outlines global blood purification push and FDA path - Stock Titan
Cytosorbents’ Earnings Call Balances Progress and Risk - The Globe and Mail
Cytosorbents Corporation (NASDAQ:CTSO) Q4 2025 Earnings Call Transcript - Insider Monkey
Cytosorbents (CTSO) Q4 2025 Earnings Transcript - AOL.com
CytoSorbents 2025 Financials: Q4 & Annual Revenue and Loss ReportNews and Statistics - IndexBox
Cytosorbents Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
Cytosorbents Corp (CTSO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.18%
0.21%
자본화:
|
볼륨(24시간):